Scarica l'app Stockscreener
27.73
16.78%
-5.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DOCS Giù?
Forum
Previsione
Precedente Chiudi:
$33.32
Aprire:
$23.69
Volume 24 ore:
23.11M
Relative Volume:
7.34
Capitalizzazione di mercato:
$5.22B
Reddito:
$550.17M
Utile/perdita netta:
$201.35M
Rapporto P/E:
27.73
EPS:
1
Flusso di cassa netto:
$232.07M
1 W Prestazione:
-25.99%
1M Prestazione:
-39.31%
6M Prestazione:
-52.30%
1 anno Prestazione:
-52.40%
Intervallo 1D:
$23.66
$27.89
Intervallo di 1 settimana:
$23.66
$38.39
Portata 52W:
$23.66
$85.21
Doximity Inc Stock (DOCS) Company Profile
Nome
Doximity Inc
Settore
Industria
Telefono
(650) 549-4330
Indirizzo
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, TEM, BTSG, HQY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
27.73 | 6.27B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
183.65 | 30.22B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
54.91 | 9.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
39.68 | 6.92B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
79.45 | 6.77B | 1.15B | 96.70M | -161.99M | 1.09 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-01-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Iniziato | BMO Capital Markets | Market Perform |
| 2025-10-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Downgrade | Goldman | Neutral → Sell |
| 2025-07-09 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-02-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Iniziato | Stephens | Equal-Weight |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-11-15 | Iniziato | Goldman | Neutral |
| 2024-11-14 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Aggiornamento | Needham | Hold → Buy |
| 2024-07-18 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2024-01-02 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-08-09 | Downgrade | Needham | Buy → Hold |
| 2023-08-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Iniziato | Wells Fargo | Overweight |
| 2022-10-24 | Iniziato | Evercore ISI | In-line |
| 2022-10-13 | Iniziato | BTIG Research | Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Iniziato | Berenberg | Buy |
| 2022-05-18 | Reiterato | BofA Securities | Neutral |
| 2022-05-18 | Reiterato | Goldman | Buy |
| 2022-05-18 | Reiterato | Guggenheim | Buy |
| 2022-05-18 | Reiterato | Jefferies | Buy |
| 2022-05-18 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Reiterato | Needham | Buy |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-04 | Iniziato | BofA Securities | Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2021-12-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-10 | Reiterato | Canaccord Genuity | Buy |
| 2021-11-10 | Reiterato | Goldman | Neutral |
| 2021-11-10 | Reiterato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Reiterato | Needham | Buy |
| 2021-11-10 | Reiterato | Piper Sandler | Overweight |
| 2021-08-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-19 | Iniziato | Goldman | Neutral |
| 2021-07-19 | Iniziato | JP Morgan | Overweight |
| 2021-07-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Iniziato | Piper Sandler | Overweight |
| 2021-07-19 | Iniziato | Raymond James | Outperform |
| 2021-07-19 | Iniziato | SVB Leerink | Outperform |
| 2021-07-19 | Iniziato | William Blair | Outperform |
Mostra tutto
Doximity Inc Borsa (DOCS) Ultime notizie
Doximity Stock (-17%): Weak Guidance Sparks an Institutional Sell-Off - Trefis
Doximity (DOCS) Stock Plummets 17% on Weak Guidance and AI Cost Surges - FinancialContent
Doximity stock dives as Q4 outlook rattles investors despite $500 million buyback - TechStock²
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Doximity (NYSE:DOCS) Shares Gap DownWhat's Next? - MarketBeat
Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates - Yahoo Finance
Why Doximity stock plummeted today - MSN
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
Why Doximity Stock Plummeted Today - AOL.com
Doximity's Soft Fiscal Q4 Guidance Adds to Investor Concerns, Morgan Stanley Says - marketscreener.com
Doximity (NASDAQ:DOCS) Shares Gap Down After Analyst Downgrade - MarketBeat
Doximity stock price target lowered to $25 by BMO Capital on near-term headwinds - Investing.com
These Stocks Are Today’s Movers: Amazon, Strategy, Novo Nordisk, Molina, Stellantis, Impinj, Doximity, and More - Barron's
Truist Cuts Price Target on Doximity to $37 From $62, Keeps Buy Rating - marketscreener.com
Why Did DOCS Stock Plunge 35% In Pre-Market Today? - Asianet Newsable
Piper Sandler lowers Doximity stock price target to $40 on slow bookings - Investing.com
Doximity (DOCS) Q3 2026 Earnings Call Transcript - AOL.com
DOCS Q4 Deep Dive: AI Momentum Overshadowed by Pharma Budget Delays and Cautious Guidance - Finviz
Doximity (NASDAQ:DOCS) Upgraded to Neutral at JPMorgan Chase & Co. - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Doximity (NASDAQ:DOCS) Stock Price - MarketBeat
Morgan Stanley Lowers Doximity (NASDAQ:DOCS) Price Target to $49.00 - MarketBeat
BTIG Research Cuts Doximity (NASDAQ:DOCS) Price Target to $50.00 - MarketBeat
Needham lowers Doximity stock price target to $55 on mixed earnings - Investing.com
Doximity, Inc. (NYSE:DOCS) Q3 2026 Earnings Call Transcript - Insider Monkey
Doximity, Inc. (DOCS) Fell Following Disappointing Guidance - Insider Monkey
Doximity (DOCS) Fell Following Disappointing Guidance - Insider Monkey
JPMorgan Upgrades Doximity to Neutral From Underweight, Adjusts Price Target to $40 From $62 - marketscreener.com
Morgan Stanley Cuts Price Target on Doximity to $49 From $65, Keeps Overweight Rating - marketscreener.com
Doximity (DOCS) stock slips premarket after soft outlook, CFO medical leave, new $500 million buyback - TechStock²
S&P 500 Futures Climb in Premarket Trading; Doximity, Stellantis Lag - Barron's
Truist Securities lowers Doximity stock price target to $37 on growth concerns - Investing.com
Doximity Buyback Highlights Confidence In Telehealth Leadership And Long Term Story - Yahoo Finance
Doximity Q3 Earnings Call Highlights - MarketBeat
Assessing Doximity: Insights From 9 Financial Analysts - Benzinga
Doximity Stock Pre-Market (-38%): Weak Guidance Overshadows Earnings Beat - Trefis
Doximity slumps on weak fourth-quarter outlook - TradingView
JPMorgan upgrades Doximity stock rating to Neutral from Underweight By Investing.com - Investing.com Nigeria
JPMorgan upgrades Doximity stock rating to Neutral from Underweight - Investing.com
Doximity Inc (DOCS) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and AI Adoption ... By GuruFocus - Investing.com Canada
Decoding Doximity Inc (DOCS): A Strategic SWOT Insight - GuruFocus
Doximity outlines 4% Q4 revenue growth and projects double-digit exit rate for 2026 amid AI platform expansion - MSN
Stock Buyback Program Approved by Doximity (NASDAQ:DOCS) - MarketBeat
Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays - TipRanks
Doximity (NASDAQ:DOCS) Announces Earnings Results - MarketBeat
Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year - 01net
Here's What Key Metrics Tell Us About Doximity (DOCS) Q3 Earnings - Yahoo Finance
Eric Topol Expects Doximity’s AI PeerCheck to Be ‘Remarkably Popular’ - Newsweek
Earnings call transcript: Doximity Q3 2026 sees earnings beat, stock dips - Investing.com
Doximity Inc-Class A (NYSE:DOCS) Plummets on Weak Revenue Outlook Despite Q3 Beat - Chartmill
Doximity, Inc. Reveals Retreat In Q3 Profit - Nasdaq
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Doximity Inc Azioni (DOCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.70%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):